Current Neuro-Oncology

Volume 27 Number 19
10 July 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 19, 10 July

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J.
A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma.
Sci Rep. 2025 Jul 1;15(1):21064. doi: 10.1038/s41598-025-06675-6. PMID: 40595067. Interventional study. ˍ ClinicalTrials.gov ID: NCT03451799.

Zhong L, Zhou P, Chen L, Chen D, Wen L, Diao X, Zhang A, Gao Y, Chen G, Li X, Huang S, Niu K, Pei Y, Liu G, Lv S, Li G. Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma: A Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2523053. doi: 10.1001/jamanetworkopen.2025.23053. PMID: 40705330. Interventional study. ˍ ChiCTR.org.cn ID: ChiCTR1800014396.

Nör C, Kharas K, Rasnitsyn A, Vladoiu MC, Cho NW, Young JS, Nör F, Mankahla N, Haapasalo J, Nordfors K, Rapic S, Skowron P, Suárez RA, Bahcheli AT, Ocsenas O, Chen X, Bahrampour S, Momin A, Sundaresan L, Ong W, Hendrikse LD, Abeysundara N, Juraschka K, Ly M, Pallota JG, Douglas T, Huang N, Wang H, Mak E, Qin L, Liu J, Shen L, Luu B, Manno A, Kumar SA, Donovan LK, Fong V, Richman C, Daniels C, Garzia L, Rich JN, Hawkins C, Wu X, DaCosta R, Reimand J, Huang X, Ramaswamy V, Raleigh DR, Taylor MD.
Therapeutic radiation drives leptomeningeal dissemination of medulloblastoma through an innate immune process.
Dev Cell. 2025 Jul 2:S1534-5807(25)00371-5. doi: 10.1016/j.devcel.2025.06.016. PMID: 40609543. Lab investigation˰ ˍ

*Kim HJ, Kim KW, Cha DH, Yoo J, Kim EH, Chang JH, Kang SG, Park JW, Kim JH, Lee Y, Lim E, Kim Y, Kim MH, Li X, Lee JH, Lee JH.
Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity.
Cancer Discov. 2025 Jul 3;15(7):1377-1391. doi: 10.1158/2159-8290.CD-24-0234. PMID: 40233712. Lab investigation˰ ˍ
RELATED ARTICLE
Lee JJY, Suvà ML. Malignant Transformation of Glioblastoma: One Step at a Time. Cancer Discov. 2025 Jul 3;15(7):1312-1314. doi: 10.1158/2159-8290.CD-25-0698. PMID: 40605506. Comment˰ ˍ

Kawaguchi Y, Hana T, Hasegawa H, Murakami C, Higashi M, Hanakita S.
Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.
J Neurosurg Case Lessons. 2025 Jul 7;10(1):CASE25247. doi: 10.3171/CASE25247. PMID: 40623326. Case report. ˍ

Shankar J, Patil N, Ayroso M, Marin R, Del Bigio M, Pitz M, Beiko J, Silvaggio J, Essig M, Kakumanu S, Sinha N.
Isolated restricted diffusion in glioblastoma: incidence, progression, and survival impact.
Neuroradiology. 2025 Jul 8. doi: 10.1007/s00234-025-03672-4. PMID: 40627192. Observational study. ˍ

Piccioni D, Juarez TM, Kesari SL, Rose L, Nomura N, Kesari S.
Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas.
Neurooncol Adv. 2025 Jul 10;7(1):vdaf150. doi: 10.1093/noajnl/vdaf150. PMID: 40709015. Interventional study. ˍ ClinicalTrials.gov ID: NCT01140568.

Scheu K, Vandieken E, Hense K, Rosengarth K, Haedenkamp T, Lenglinger M, Bumes E, Linker R, Proescholdt M, Schmidt NO, Riemenschneider MJ, Wendl C, Wiesinger I, Hau P.
MRI-defined patterns of infiltration and outcome in patients with glioblastoma.
Neurooncol Adv. 2025 Jul 10;7(1):vdaf114. doi: 10.1093/noajnl/vdaf114. PMID: 40842643. Observational study. ˍ